PT  - JOURNAL ARTICLE
AU  - Person, Osmar Clayton
AU  - Angélico Júnior, Fernando Veiga
AU  - Santos, Rodrigo Lima de Godoy
AU  - de Rezende, William Marasini
AU  - Giusti, Maria Fernanda
AU  - Puga, Maria Eduarda dos Santos
TI  - EFFECTIVENESS OF ACAMPROSATE FOR TINNITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL TRIALS
AID  - 10.1101/2021.06.09.21258585
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.09.21258585
4099  - http://medrxiv.org/content/early/2021/06/12/2021.06.09.21258585.short
4100  - http://medrxiv.org/content/early/2021/06/12/2021.06.09.21258585.full
AB  - Introduction The effectiveness of tinnitus treatment represents a huge gap in the medical science. Acamprosate is a glutamatergic antagonist drug and GABA-agonist that could be used to control tinnitus due to its action on peripheral and central neurotransmission.Purpose To assess the effectiveness of acamprosate in the treatment of tinnitus.Material and Methods This is a systematic review and we searched for randomized clinical trials linking acamprosate to tinnitus in six databases: Cochrane - Central Register of Controlled Trials - CENTRAL (2021), PUBMED (1966-2021), EMBASE (1974-2021), IBECS (1982-2021), QINSIGHT (2021) and SCOPUS (2021). Two researchers independently extracted the data and assessed the quality of the studies.Results Two trials involving 121 patients were included. The methodological quality of these studies was low. Both studies evaluated as primary outcome the efficacy of acamprosate in improving tinnitus. The meta-analysis by random model resulted in no significant difference between the groups treated with acamprosate and placebo (RR = 3,69, 95% CI 0,87-15,62; p=0,08), considering tinnitus improvement. Conclusions: There is no evidence that acamprosate is effective for tinnitus treatment. We recommend new trials using rigorous methodology. Randomization and blinding should be of the highest quality, given the subjective nature of tinnitus and the strong likelihood of a placebo response. The CONSORT statement should be used in the design and reporting of future studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Authors there was no financingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Universidade Santo Amaro UNISA Sao Paulo BrazilAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdoes not apply because it is a Systematic Review